REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  05/23 04:00:01 pm EDT
681.91 USD   +3.14%
09:58aSVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
09:15aFda approves dupixent (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
AQ
09:14aEvkeeza (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ultra-rare form of high cholesterol
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment

01/19/2022 | 07:37am EDT

By Colin Kellaher


Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration accepted for review its application for expanded use of the cancer drug Libtayo, in combination with chemotherapy, as first-line treatment in advanced non-small cell lung cancer.

The Tarrytown, N.Y., biotechnology company, which is developing and commercializing Libtayo with France's Sanofi SA under a global collaboration agreement, said the agency set a target action date of Sept. 19.

The companies also recently filed for European regulatory approval in the indication.

Regeneron said the application is supported by results from a randomized, multicenter Phase 3 study that was stopped early after the combination showed a significant overall survival improvement compared to chemotherapy alone.

Non-small cell lung cancer accounts for roughly 84% of all lung cancer, the leading cause of cancer death worldwide, Regeneron said.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

01-19-22 0737ET

Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION -1.01% 55.89 Delayed Quote.-17.71%
REGENERON PHARMACEUTICALS, INC. 3.14% 681.91 Delayed Quote.7.98%
SANOFI 1.37% 103.7 Real-time Quote.15.49%
All news about REGENERON PHARMACEUTICALS, INC.
09:58aSVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
09:15aFda approves dupixent (dupilumab) as first treatment for adults and children aged 12 an..
AQ
09:14aEvkeeza (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ul..
AQ
07:37aFDA approves Dupixent« (dupilumab) as first treatment for adults and children aged 12 ..
AQ
06:54aSVB Securities Initiates Regeneron Pharmaceuticals at Outperform With $738 Price Target
MT
04:54aRegeneron's Phase 3 Trial Data Shows Positive Results for Potential Treatment of Rare H..
MT
05/21Evkeeza« (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with U..
PR
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
05/20FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 835 M - -
Net income 2022 4 041 M - -
Net cash 2022 8 670 M - -
P/E ratio 2022 18,4x
Yield 2022 -
Capitalization 73 473 M 73 473 M -
EV / Sales 2022 5,48x
EV / Sales 2023 4,84x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 681,91 $
Average target price 691,67 $
Spread / Average Target 1,43%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.7.98%71 235
GILEAD SCIENCES, INC.-12.08%80 075
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-17.77%42 735
BIONTECH SE-36.77%39 612
GENMAB A/S-17.26%20 205